Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regeneron Pharmaceuticals, Inc. (REGN) trades at $835.15 with AI Score 94/100 (Grade A+). Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering and developing innovative medicines for various diseases. Market cap: $86.0B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 10, 2026REGN stock analysis for 2026: Analysts have set a consensus price target of $854.53 for Regeneron Pharmaceuticals, Inc., suggesting 2.3% upside from the current price of $835.15. The AI MoonshotScore is 94/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
REGN: 3/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Regeneron Pharmaceuticals, Inc. (REGN) Healthcare & Pipeline Overview
Regeneron Pharmaceuticals, Inc. stands out in the biotechnology sector with its innovative drug portfolio, including treatments for eye diseases and asthma, and a strong commitment to research and development, positioning itself as a key player in addressing unmet medical needs globally.
What Is the Investment Thesis for REGN?
Regeneron Pharmaceuticals, Inc. presents a compelling investment thesis driven by its robust product portfolio and strong financial metrics. With a market capitalization of $86.0B and a P/E ratio of 16.4, the company demonstrates solid profitability, evidenced by a profit margin of 29.6% and a gross margin of 84.5%. The ongoing success of EYLEA and Dupixent, along with new product launches and an extensive pipeline, are expected to drive revenue growth in the coming years. Additionally, Regeneron's strategic collaborations with industry leaders provide opportunities for expanding its market reach and enhancing its research capabilities. However, potential risks include regulatory hurdles and competition from generic drugs, which could impact future earnings. Overall, Regeneron’s commitment to innovation and its strong financial position make it a noteworthy player in the biotechnology sector.
Based on FMP financials and quantitative analysis
REGN Key Highlights
Market capitalization of $86.0B reflects strong investor confidence and market position.
- P/E ratio of 16.4 indicates a favorable valuation compared to industry peers.
- Profit margin of 29.6% showcases operational efficiency and effective cost management.
- Gross margin of 84.5% highlights the high profitability of its product offerings.
- Beta of 0.40 suggests lower volatility compared to the broader market, appealing to risk-averse investors.
Who Are REGN's Competitors?
REGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELV Elevance Health Inc. | $397.54 | -0.23% | $86.2B | 86 |
| CI Cigna Corporation | $277.45 | -0.38% | $73.3B | 78 |
| COR Cencora, Inc. | $316.79 | -0.10% | $61.6B | 80 |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ARGX argenx SE | $1038.12 | +0.51% | $64.6B | 49 |
| VRTX Vertex Pharmaceuticals Incorporated | $552.06 | +4.52% | $140B | 98 |
| ALNY Alnylam Pharmaceuticals, Inc. | $242.61 | +6.12% | $32.5B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REGN's Key Strengths?
Strong product portfolio with established market leaders like EYLEA and Dupixent.
- High gross margins indicating operational efficiency.
- Robust pipeline of innovative therapies targeting unmet medical needs.
- Strategic collaborations with major pharmaceutical companies enhance growth potential.
What Are REGN's Weaknesses?
Dependence on a limited number of key products for revenue generation.
- Potential regulatory hurdles that could delay product approvals.
- High R&D costs that may impact profitability in the short term.
- Exposure to pricing pressures in the pharmaceutical industry.
What Could Drive REGN Stock Higher?
Continued expansion of EYLEA's indications through ongoing clinical trials.
- Strong sales growth from Dupixent as it gains traction in new therapeutic areas.
- Potential new product launches from Regeneron's extensive pipeline.
- Strategic collaborations with pharmaceutical partners enhancing research capabilities.
- Regulatory approvals for new therapies in development.
What Are the Key Risks for REGN?
Insider selling — insiders were net sellers of roughly $1.2M recently.
- Regulatory hurdles that could delay product launches.
- Intense competition from other biotechnology firms and generic products.
- Changes in healthcare policy affecting reimbursement rates.
- Market volatility impacting stock performance and investor sentiment.
What Are the Growth Opportunities for REGN?
- Expansion of EYLEA: The global market for age-related macular degeneration treatments is projected to reach $10 billion by 2027. Regeneron aims to expand EYLEA's indications and enhance its market share through ongoing clinical trials and new formulations, potentially increasing revenue significantly over the next five years.
- Regeneron is actively pursuing these new indications, which could drive sales growth and strengthen its market position.
- Rare Disease Pipeline: Regeneron is developing therapies for rare diseases, a segment that is gaining attention due to unmet medical needs. Regeneron's focus on innovative treatments in this area could lead to significant revenue contributions in the coming years.
- COVID-19 Treatment Development: The ongoing demand for COVID-19 treatments and potential future pandemics present an opportunity for Regeneron to leverage its REGEN-COV product. Continued development and potential new indications could enhance its revenue streams as global health needs evolve.
- Strategic Collaborations: Regeneron’s partnerships with major pharmaceutical companies, including Sanofi and Bayer, provide access to additional resources and markets. These collaborations are expected to enhance product development and distribution capabilities, driving growth and expanding Regeneron's global footprint.
What Threats Does REGN Face?
- Intense competition from established pharmaceutical companies and new entrants.
- Risks associated with patent expirations and generic competition.
- Regulatory changes that could impact pricing and reimbursement.
- Market volatility affecting investor sentiment and stock performance.
What Are REGN's Competitive Advantages?
- Robust pipeline of innovative products supported by strong R&D capabilities.
- Established reputation and brand recognition in the biotechnology sector.
- Strategic partnerships with leading pharmaceutical companies enhance market access.
- Strong intellectual property protections for proprietary medicines.
- High gross margins due to the premium pricing of specialized therapies.
What Does REGN Do?
Founded in 1988 and headquartered in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. has established itself as a leader in the biotechnology industry by discovering, inventing, developing, manufacturing, and commercializing medicines for a wide range of diseases. The company's flagship products include EYLEA, which is used to treat various eye conditions such as wet age-related macular degeneration and diabetic macular edema, and Dupixent, a breakthrough treatment for atopic dermatitis and asthma. Over the years, Regeneron has expanded its product offerings to include Libtayo for skin cancer, Praluent for cholesterol management, and REGEN-COV for COVID-19, among others. The company has a strong focus on research and development, with a pipeline that includes candidates for eye diseases, allergic and inflammatory conditions, cardiovascular diseases, and cancer. Regeneron has formed strategic collaborations with major pharmaceutical companies such as Sanofi and Bayer, enhancing its ability to innovate and bring new therapies to market. With a workforce of over 15,000 employees, Regeneron is committed to improving patient outcomes through science and innovation, making significant contributions to the healthcare landscape globally.
What Products and Services Does REGN Offer?
- Discover, invent, and develop medicines for various diseases.
- Manufacture and commercialize innovative therapies for eye diseases.
- Provide treatments for asthma and allergic conditions.
- Develop oncology products for various types of cancer.
- Collaborate with other pharmaceutical companies to enhance research capabilities.
- Focus on rare diseases and unmet medical needs through targeted therapies.
How Does REGN Make Money?
- Generate revenue through the sale of proprietary pharmaceutical products.
- Engage in strategic collaborations and licensing agreements with other companies.
- Invest heavily in research and development to innovate new therapies.
- Leverage a strong intellectual property portfolio to protect product innovations.
- Utilize a direct-to-consumer approach for certain products to enhance market reach.
What Industry Does REGN Operate In?
The biotechnology industry is characterized by rapid innovation and a strong focus on research and development, with a global market projected to reach $2.4 trillion by 2028. Regeneron Pharmaceuticals, Inc. operates in a competitive landscape, facing rivals such as Elevance Health Inc., Cigna Corporation, and Zoetis Inc. The increasing demand for advanced therapeutics, particularly in areas like oncology and chronic diseases, positions Regeneron favorably as it continues to expand its product pipeline and leverage its scientific expertise to meet emerging healthcare needs.
Who Are REGN's Key Customers?
- Healthcare providers and hospitals that prescribe and administer therapies.
- Patients suffering from chronic diseases and conditions requiring innovative treatments.
- Pharmaceutical partners engaged in collaborative research and development.
- Government agencies and health organizations for public health initiatives.
- Insurance companies that reimburse for approved therapies.
Company Profile
Regeneron Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tarrytown, US. The company is led by CEO Leonard S. Schleifer. REGN has traded publicly since 1991.
Regeneron Pharmaceuticals, Inc. Financial Trajectory
Regeneron Pharmaceuticals, Inc. (REGN) reported $4.29B in revenue for Q2 2026, reflecting 19.0% growth compared to the prior quarter. The company recorded net income of $1.30B, with diluted EPS of $12.20. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, REGN averaged $10.11 in diluted EPS.
How Regeneron Pharmaceuticals, Inc. Is Valued
Regeneron Pharmaceuticals, Inc. carries a market capitalization of $86.0B, placing it in the large-cap category. Relative to its peer group, REGN's quantitative score of 94/100 is above the peer average of 76/100.
Key Financial Metrics
Return on equity for Regeneron Pharmaceuticals, Inc. stands at 13.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.4%, showing how much profit it generates from its asset base. REGN trades at a trailing price-to-earnings ratio of 16.35, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Regeneron Pharmaceuticals, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.59 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Regeneron Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 17.3% above estimates on average.
Forward Outlook
Wall Street analysts project Regeneron Pharmaceuticals, Inc. revenue of about $16.83B for fiscal 2026, with EPS near $52.65. The estimate reflects 18 contributing analysts.
Insider Activity
Over the past six months, Regeneron Pharmaceuticals, Inc. insiders filed 15 SEC Form 4 transactions — 13 sales and 2 purchases. On net that is roughly 1K shares disposed (about $1.2M), a signal worth weighing alongside the fundamentals.
REGN Financials
REGN earnings history & estimates →
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong product portfolio with established market leaders like EYLEA and Dupixent.
- High gross margins indicating operational efficiency.
- Robust pipeline of innovative therapies targeting unmet medical needs.
- Strategic collaborations with major pharmaceutical companies enhance growth potential.
Bear Case
- Dependence on a limited number of key products for revenue generation.
- Potential regulatory hurdles that could delay product approvals.
- High R&D costs that may impact profitability in the short term.
- Exposure to pricing pressures in the pharmaceutical industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
From the Earnings Call
“Libtayo maintained its strong growth trajectory in the second quarter. Global net product sales reached nearly $500 million, up 29% compared to last year on a constant currency basis. ... In first-line non-small cell lung cancer, Libtayo is now firmly established as the second most prescribed immunotherapy treatment in the U.S., where Libtayo's share of new patient starts has doubled since early 2025 to 20% as physic…”
— Marion McCourt, Executive Vice President, Commercial
“Dupixent global net product sales as reported by Sanofi, were $6 billion, up 38% compared to the second quarter of last year on a constant currency basis. ... Given that success, I can report that we have had productive early discussions with Sanofi to identify potential opportunities for further collaboration, including for several of Regeneron's Dupixent follow-on programs.”
— Leonard Schleifer, Co-Founder, Board, Co-Chair, President and Chief Executive Officer
REGN Q2 FY2026 earnings call transcript · 2026-07-30
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $4.29B | $1.30B | $12.20 |
| Q1 2026 | $3.61B | $727M | $6.75 |
| Q4 2025 | $3.88B | $845M | $7.86 |
| Q3 2025 | $3.75B | $1.46B | $13.62 |
Based on FMP financials and quantitative analysis
REGN Latest News
-
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
Simply Wall St. · Aug 20, 2026
-
Biotech Stocks Are Booming. What This Top Fund Is Buying Now.
Barrons.com · Aug 19, 2026
-
2 GLP-1 Stocks That Could Double Your Money by 2031
Motley Fool · Aug 16, 2026
-
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com · Aug 16, 2026
REGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REGN.
Price Targets
Consensus target: $854.53
REGN MoonshotScore
What does this score mean?
The MoonshotScore rates REGN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
Biotech Stocks Are Booming. What This Top Fund Is Buying Now.
2 GLP-1 Stocks That Could Double Your Money by 2031
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Latest Regeneron Pharmaceuticals, Inc. Analysis
Related Investment Themes
Leadership: Leonard S. Schleifer
CEO
Leonard S. Schleifer co-founded Regeneron Pharmaceuticals, Inc. in 1988. He holds an M.D. and a Ph.D. from the University of Virginia and has extensive experience in the biotechnology industry. Under his leadership, Regeneron has grown from a small startup into a leading biopharmaceutical company with a strong focus on innovation and research.
Track Record: Leonard has overseen the successful development and commercialization of multiple blockbuster drugs, including EYLEA and Dupixent, significantly contributing to the company's growth and market position.
Common Questions About REGN (Healthcare)
What does the AI Score mean for REGN?
REGN holds an AI Score of 94/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering and developing innovative medicines for various diseases. With a strong portfolio of products and a robust …
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. is a biotechnology company that focuses on discovering, developing, and commercializing innovative medicines for various diseases. Its product portfolio includes treatments for eye diseases, asthma, cancer, and rare diseases, with a strong emphasis on research and development to address unmet medical needs.
What do analysts say about REGN stock?
Analysts generally view REGN stock positively, citing its strong product pipeline and financial performance. Key valuation metrics indicate a favorable position within the biotechnology sector, with a P/E ratio of 16.4 and a profit margin of 29.6%. Growth considerations include the expansion of existing products and the potential for new drug approvals.
What are the main risks for REGN?
Regeneron Pharmaceuticals, Inc. faces several risks, including regulatory hurdles that could impact product approvals and market entry. Additionally, the company is exposed to intense competition from both established pharmaceutical companies and generic alternatives. Changes in healthcare policies may also affect reimbursement rates, posing further challenges to revenue generation.
What are the key factors to evaluate for REGN?
Regeneron Pharmaceuticals, Inc. (REGN) holds an AI score of 94/100 (high). P/E: 16.4x vs the S&P 500's ~20-25x. Analysts target $854.53 (+2%). Not financial advice.
How frequently does REGN data refresh on this page?
REGN's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven REGN's recent stock price performance?
Regeneron Pharmaceuticals, Inc. (REGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong product portfolio with established market leaders like EYLEA and Dupixent. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider REGN overvalued or undervalued right now?
Regeneron Pharmaceuticals, Inc. (REGN) trades at 16.4x earnings. Analysts target $854.53 (+2%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research REGN before investing?
Before investing in Regeneron Pharmaceuticals, Inc. (REGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of May 2026.